Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), brings breaking news with yesterday’s recent announcement of a fully committed capital increase of €25M in two phases, at €44 a share, representing an approximate 14% premium to [...]
Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) has been named winner of the Trends-Tendances Business Tour 2013 Award in the “Innovation” category for the Brabant Walloon region. The Business Tour showcases three companies in each province in the country in [...]
Latest news from Mont-Saint-Guibert, Belgium – Cardio3 BioSciences SA has recently announced that it is considering raising new funds through an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris. This is an update to the [...]
Two exciting new announcements have recently been made by Belgian-based biotechnology company Cardio3 BioSciences(Mont-Saint Guibert, Wallonia). In early April the company announced the publication of Phase II trial results for stem cell therapy C-Cure® in the [...]
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, recently announced the acquisition of Neurotech SA, a developer of neurostimulation devices out of Belgium. Created as a spin-off in [...]